Yes, a 1 for 6 reverse split, not at all affecting market cap and only aiding in the likelyhood that the stock can stay on the Nasdaq, yet of course the news is somehow percieved as negative and so the stock takes a dump more than 16%?! I mean, come on fools, sheesh. What a bunch of fools. What idiot moron is just dumping shares at any price?! I looked at the short volume, I did not see any institutions or anyone actively still shorting this name because it was already shorted heavily from about a dollar months ago then they covered down at roughly 50 cents making a ton of money, probably front running the inside info that there was going to be an issuance to a private equity firm at just above 50 cents. This whole stock story stinks. What the %#$! is going on here?! Anyone?! Anyone home?!
It hit a high of $0.69 cents just a week or two ago and after news of a reverse split the stock tanks to $0.47 cents?! The reverse split means absolutely nothing to valuation. I mean, what is the price?! What price would you like to buy and/or sell the stock for? Make a decision, make a determination, this constant selling for cheaper and cheaper prices just does not make ANY sense to me whatsoever. Am I just a lone nut here thinking this?!
I dont get it. I will be very happy once one of AGEN's 15 possible adjuvant-contained vaccine candidates finally gets FDA approval and Agenus begins taking in HUGE royalties, the revenue will be coming in hand over fist and this stock will go up to ten dollars. THEN MAYBE FINALLY the AGEN stock can trade in a proper range, for now it is just more of the same; BS sell on any news for any price for no reason, just rip out all your money all at once so as to have more liquidity in a toxic market so you can have more firepower to use for shorting another speculative stock, it really gets tiresome sometimes, arrghhhh.
sheesh, good luck to all, I hope luck actually still exists these days, it seems all stocks on this market are just play things for 800 lbs gorillas, and you know what happens to play things of beasts, yea they get ripped to shreds and then tossed out with the garbage. FDA, please approve the herpes vaccine, improve millions of lives, rescue some AGEN investors, make Glaxo shareholders richer, its a great deal all around.
GLTA
It hit a high of $0.69 cents just a week or two ago and after news of a reverse split the stock tanks to $0.47 cents?! The reverse split means absolutely nothing to valuation. I mean, what is the price?! What price would you like to buy and/or sell the stock for? Make a decision, make a determination, this constant selling for cheaper and cheaper prices just does not make ANY sense to me whatsoever. Am I just a lone nut here thinking this?!
I dont get it. I will be very happy once one of AGEN's 15 possible adjuvant-contained vaccine candidates finally gets FDA approval and Agenus begins taking in HUGE royalties, the revenue will be coming in hand over fist and this stock will go up to ten dollars. THEN MAYBE FINALLY the AGEN stock can trade in a proper range, for now it is just more of the same; BS sell on any news for any price for no reason, just rip out all your money all at once so as to have more liquidity in a toxic market so you can have more firepower to use for shorting another speculative stock, it really gets tiresome sometimes, arrghhhh.
sheesh, good luck to all, I hope luck actually still exists these days, it seems all stocks on this market are just play things for 800 lbs gorillas, and you know what happens to play things of beasts, yea they get ripped to shreds and then tossed out with the garbage. FDA, please approve the herpes vaccine, improve millions of lives, rescue some AGEN investors, make Glaxo shareholders richer, its a great deal all around.
GLTA
Recent AGEN News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/13/2026 06:59:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/11/2026 09:04:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 12:52:03 PM
- Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development • Business Wire • 05/11/2026 12:45:00 PM
- Agenus to Provide First Quarter 2026 Financial Report and Corporate Update • Business Wire • 05/04/2026 08:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 08:35:04 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:34:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:02 PM
- アジーナス、BOT+BALアクセスプログラムの独占的グローバルパートナーにBAP Pharmaを指名 • Business Wire • 04/22/2026 03:56:00 PM
- Agenus ernennt BAP Pharma zum exklusiven globalen Partner für die BOT+BAL-Zugangsprogramme • Business Wire • 04/22/2026 12:55:00 AM
- Agenus désigne BAP Pharma comme partenaire mondial exclusif pour les programmes d’accès à la combinaison BOT+BAL • Business Wire • 04/22/2026 12:55:00 AM
- Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026 • Business Wire • 04/21/2026 02:00:00 PM
- Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs • Business Wire • 04/21/2026 12:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/20/2026 09:21:47 PM
- Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer • Business Wire • 04/17/2026 08:43:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 08:15:10 PM
- Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 • Business Wire • 04/03/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:29 PM
- アジーナス、MSSまたはpMMRの転移性大腸がんを対象としたBOT+BAL免疫療法併用のグローバル第3相BATTMAN試験で初の患者登録を発表 • Business Wire • 04/02/2026 04:31:00 AM
